A 20:1 combination of CBD and cannabidivarin (CBDV) reduced colitis severity in mice by suppressing the immune cell trafficking receptor CXCR4 through the CB2 receptor.
IBD researchers, cannabinoid scientists studying the entourage effect, and gastroenterologists.
What the researchers found
The CBD:CBDV 20:1 combination significantly reduced CXCR4 expression in multiple immune cell types, impaired chemotaxis, and improved disease activity, colon length, and histological outcomes in DSS-induced colitis. All benefits were abolished in CB2 knockout mice.
Why it matters
This provides a mechanistic explanation for the "entourage effect" in a specific disease context. The minor cannabinoid CBDV enhanced CBD's therapeutic effect through a defined molecular pathway.
The numbers in context
CBD:CBDV ratio of 20:1. CXCR4 reduction confirmed across three cell types. Benefits absent in CB2 knockout mice.
How the study worked
In vitro experiments in MOLT-4 cells, murine splenocytes, and human PBMCs. In vivo DSS-induced colitis model in wild-type and CB2 knockout mice. CB2 receptor inhibition confirmed mechanism.
What this study cannot tell us
DSS-induced colitis is a chemical model that does not fully replicate human IBD. The 20:1 ratio was tested but other ratios were not systematically compared.
How to read the evidence
Strong mechanistic validation using both in vitro and in vivo models plus CB2 knockout confirmation.
When this study was published
2025 publication.
The bigger picture
The entourage effect has been debated for years with limited mechanistic evidence. This study provides one of the clearest demonstrations that a specific minor cannabinoid enhances a major cannabinoid through a defined receptor mechanism.
Questions still open
- Would the CBD:CBDV combination show similar benefits in other IBD models?
- Is the 20:1 ratio optimal?
Common questions
What is CBDV?
What is the entourage effect?
Read the original research
Combination of CBD with minor cannabinoid CBDV suppresses CXCR4 via CB2 receptor and alleviates colitis in mice.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 193, 118768
Citation
Gelfand, Anat; Besser, Elazar; Procaccia, Shiri; Cohen, Jonathan; Steinberg, Miryam; Kleifeld, Oded; Meiri, David. (2025). Combination of CBD with minor cannabinoid CBDV suppresses CXCR4 via CB2 receptor and alleviates colitis in mice.. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 193, 118768. https://doi.org/10.1016/j.biopha.2025.118768
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk